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Abstract 20 
As engineered nanomaterials are increasingly introduced on the market into a broad range of 21 
commodities or nanoproducts, there is a need for operational, reliable tool, enabling to 22 
consistently assess the risks and impacts associated with the releases of nanoparticles. The lack 23 
of a developed metric that accurately represents their toxic effects while capturing the influence 24 
of the most relevant physicochemical properties is one of the major impediments. Here, we 25 
investigate the relationships between the toxic responses of nano-sized and micro-sized particles 26 
in in vivo toxicological studies and their physicochemical properties. Our results for TiO2 27 
particles indicate statistically-significant associations between the primary particle size and their 28 
toxicity responses for combined inhalation and ingestion exposure routes, although the numerical 29 
values should be considered with care due to the inability to encompass influences from other 30 
relevant physicochemical properties like surface coatings. These findings allow for expressing 31 
mass-based adverse effect levels as a continuous function of the primary size of particles. This 32 
meaningful, exploratory metric can thus be used for screening purposes and pave the way for 33 
reaching adaptive, robust risk assessments of nanomaterials, e.g. for setting up consistent 34 
threshold levels, as well as consistent life cycle assessments of nanoproducts. We provide 35 
examples of such applications. 36 
 37 
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1. Introduction 41 
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The commercialization of engineered nanomaterials has dramatically increased over the past 42 
years (Hendren et al., 2011; Keller et al. 2013; Mitrano et al., 2015). Simultaneously, the 43 
potential releases of nanoparticles and their consequent risks and impacts along the life cycle of 44 
nanoproducts (products embedding nanomaterials) have been raised in many studies (Grieger et 45 
al. 2012; Maynard et al. 2006; Nel et al. 2006; Oberdörster 2010; Oberdörster et al. 2005; 46 
SCENIHR 2009; Stone et al. 2010a; Wiesner et al. 2006). Several works have thus attempted to 47 
perform human and ecological risk assessments of several nanomaterials, e.g. nano-scale 48 
titanium dioxide (Christensen et al. 2011; US-EPA 2010; Warheit 2013). Likewise, a number of 49 
studies have performed life cycle assessments of nanoproducts, quantifying the environmental 50 
impacts from their manufacture, use and disposal stages (e.g. Walser et al. 2011). However, these 51 
attempts do not gather sufficient robustness and reliability to allow for conclusive assessments of 52 
the risks and impacts stemming from the released nanoparticles because of difficulties in 53 
estimating their actual emissions and in identifying, tracking and evaluating the many parameters 54 
influencing their fate, transport and toxicity (Aschberger et al. 2011; Jolliet et al. 2014; 55 
Savolainen et al. 2010; Warheit 2013).  56 
To support the evaluation of the health effects, a large number of toxicological studies have 57 
been conducted (see review by Krug, 2014). Several reviews have been published over the years 58 
to synthesize current knowledge and give overviews of the toxic effects of fine particles and/or 59 
nanoparticles (e.g. see non-exhaustive list in Supplementary Methods; Krug, 2014). Very few of 60 
these have performed comprehensive, quantitative analyses of the findings to identify possible 61 
common patterns. Most works provide thorough snapshots of existing studies at a given time, but 62 
limit their analyses to qualitative discussions. Among the most comprehensive ones, the study by 63 
Krug (2014) has thus analyzed general trends observed over more than 10000 publications and 64 
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showed that, despite the sheer number of studies, a number of challenges still remains in their 65 
interpretation, particularly due to a lack of comparability across studies and a widespread 66 
omission of consistent characterization of the nanoparticles (Krug, 2014). The generally poor 67 
reporting of physicochemical properties known to influence the toxicity of nanoparticles has 68 
often been raised (e.g. Clark et al. 2012; Krug, 2014).   Among the relevant physicochemical 69 
properties, the primary particle size, shape, specific surface area, surface chemistry and 70 
reactivity, composition, coating composition, crystallinity, charge, solubility and state of 71 
agglomeration and aggregation have been flagged as the most important (e.g. Maynard and 72 
Aitken 2007; MINChar 2008; Landsiedel et al. 2010; Oberdörster 2010; Stone et al. 2010a). The 73 
primary particle size, one of the most studied properties, has been demonstrated to significantly 74 
contribute to the toxic effects (Oberdörster et al. 2005). This relationship indicates that the mass 75 
of particles alone cannot be a sufficient metric to characterize their toxic effects since the intake 76 
(i.e. amount of nanoparticle entering the body) of a same mass of particles of different sizes may 77 
result in different toxic effects (Oberdörster et al. 2005). To date, there is still a need to better 78 
characterize the effects of nanoparticles on human health once they are inhaled or ingested as a 79 
function of their physicochemical properties (Jolliet et al. 2014). 80 
In this study, we propose a methodology to quantitatively investigate the relationships 81 
between the non-carcinogenic effects of nano-sized and micro-sized particles and selected 82 
physicochemical properties so that it can ultimately serve as support for risk assessment and life 83 
cycle assessment of nanomaterials and nanoproducts. We focus on nano-scale titanium dioxide 84 
(TiO2), which is among the mostly used nanomaterials on the market and one of the mostly 85 
investigated in toxicological studies (Hendren et al., 2011; Keller et al. 2013; Mitrano et al. 86 
2015). We specifically aim to (i) review the experimental settings and findings of all available in 87 
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vivo studies published on this material that met selection criteria with respect to exposure routes, 88 
exposure time and observed toxic endpoints; (ii) analyze ways to investigate relationships 89 
between non-carcinogenic effects of nanoparticles and selected physicochemical properties, (iii) 90 
explore the derivation and application of no-observed adverse effect levels (NOAELs) for nano-91 
sized and micro-sized particles to be used in risk assessment and life cycle assessment. 92 
 93 
2. Methodology 94 
2.1. Overview of the methodology 95 
The overall methodology consists of a 6-step approach, which includes (1) identification and 96 
selection of in vivo studies, (2) characterisation of particles with respect to their reported 97 
physicochemical properties, (3) expression of the doses into “intake doses” to allow comparisons 98 
across exposure routes, (4) review of the displayed toxicity responses for each experiment using 99 
information on the endpoints reflecting adverse effects resulting from exposure to the 100 
nanoparticle, (5) statistical analyses of the relationships between the reported physicochemical 101 
properties and the incidence or absence of adverse effects, and (6) extrapolations to human 102 
equivalent doses. Each of these steps is succinctly described in the following subsections. 103 
In the following, the term ‘experiment’ refers to a test on a given species exposed to a 104 
specific type of particles (in terms of sizes, surface treatment and crystal form –see below section 105 
on particle characterisation). An experiment may include several exposure levels (i.e. different 106 
doses). The term ‘study’ refers to a set of experiments performed by the same research group, 107 
and may include different particle types, exposure pathways and test animals. 108 
 109 
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2.2. Identification, selection and classification of studies 110 
The identification of in vivo studies was done through literature search engine, and (see 111 
Supplementary Methods) complemented by the cross-checking of citing and cited literature as 112 
well as studies cited in review papers in the field of nanotoxicology.  Complete documentation of 113 
those steps is available in Supplementary Methods. 114 
In vitro studies were disregarded because they relate to acute toxicity and methods to use 115 
them for predicting chronic (i.e. long-term) in vivo toxicity are yet undeveloped (Oberdörster 116 
2010). Ways of incorporating the large pool of data stemming from them should however be 117 
better investigated (Oberdörster 2010; Krug, 2014). Out of the retrieved in vivo studies, filtering 118 
criteria were applied to retain (i) studies with sufficiently long exposure durations, (ii) studies for 119 
which the monitored toxic endpoints are comparable with other studies, (iii) studies, for which 120 
reporting contains sufficient information for particle characterisation and analysis of the results, 121 
(iv) studies addressing oral and inhalation exposure pathways, which are both considered the 122 
most relevant for risk assessment and life cycle assessment applications. For the latter, because 123 
no consensus currently exist on the correspondence between inhalation and intratracheal 124 
instillation studies, the intratracheal instillation tests, in which the particles are directly 125 
administered into the lower part of the respiratory tract of the animal under anaesthesia, were 126 
disregarded in the current study (see, e.g. Aitken et al. 2009; Bakand et al. 2012; Driscoll et al. 127 
1991, 2000; Warheit et al. 2005). However, further work should continue exploring the 128 
comparability of the results in the large body of intratracheal instillation experiments (> 50 129 
studies) with the findings from inhalation studies to bring additional data for interpretation 130 
(Krug, 2014). 131 
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With respect to exposure durations, the retrieved studies were classified into four groups, i.e. 132 
acute, subacute, subchronic or semi-chronic, and chronic. The categorisation is strongly 133 
dependent on the species, e.g. maximum lifetime (Vermeire et al. 1999). Supplementary 134 
Methods (Table M3) show the categories and their associated definitions that are assumed for 135 
studies on rats, mice and hamsters. Acute studies, i.e. with a repeated exposure of less than 7 136 
consecutive days, were disregarded in the current study as the overall aim is to investigate 137 
chronic toxicity. 138 
Only studies with a comprehensive report of the toxicity responses were included. 139 
Biodistribution and dosimetry-based studies were not considered when they did not investigate 140 
possible incidence of adverse toxic effects. Studies, in which only morphological effects of 141 
exposure to micro-sized or nano-sized particles were observed (e.g. weight), were disregarded. In 142 
addition, genotoxicity tests were excluded because of the difficult comparability with other 143 
toxicological studies and their linkage to potential mutagenicity carcinogenic effects, which are 144 
considered outside the scope of the study (Koedrith et al. 2014). Only studies including 145 
investigations of non-cancer effects were considered (although studies investigating cancer 146 
effects are also reported in Tables S1 and S2). Furthermore, all tests performed on animal models 147 
of human susceptibility, e.g. pregnant mice (Gao et al. 2011; Warheit et al., 2015) were 148 
excluded. Finally, all tests with responses and/or doses and/or particle characterisation that could 149 
not be quantified properly were excluded. 150 
 151 
2.3. Particles properties available for statistical analysis 152 
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Over the past decade, the field of nanotoxicology has identified a relatively large number of 153 
physicochemical properties of the nanoparticles that are accountable for their toxic effects. From 154 
the literature, about 10 generic physicochemical properties are frequently reported as influential 155 
to the fate and health effects of the nanoparticles, i.e. the primary particle size (incl. size 156 
distribution), the shape (aspect ratio), the specific surface area, the surface chemistry/reactivity, 157 
the composition (incl. impurities), the coating composition (if any), the crystal structure, the 158 
charge, the solubility, the state of agglomeration (Zeta potential) and aggregation (Landsiedel et 159 
al. 2010; Maynard and Aitken 2007; MINChar 2008; Oberdörster 2010; Stone et al. 2010a, b). 160 
A case-by-case approach is advised when addressing the behaviour of nanoparticles in the 161 
environment and their impacts on human health (and ecosystems) –see e.g. Stone et al. (2010a) 162 
and SCENIHR (2009). Therefore, not all properties will play a same role whether carbon 163 
nanotubes or nano-TiO2 are studied, for example. One of the major problems to analyse the 164 
influence of these properties is the lack of comprehensive documentation in the experimental 165 
studies, which render difficult the find of patterns (Clark et al. 2012). Although it is not directly 166 
addressed in this study, another issue consists in the contrast between the properties of pristine 167 
nanoparticles, which are manufactured nanomaterials and are the focus of most toxicological 168 
studies, and those of the nanoparticles eventually embedded in consumer products and 169 
potentially released to the environment in their use or disposals (Nowack et al. 2012). Properties 170 
of the latter categories of particles (and their changeability after releases) are more relevant to 171 
human health impact and risk assessments.(Nowack et al. 2012) 172 
With respect to TiO2 nanoparticles, a number of studies have highlighted the influence on 173 
the toxicity responses of several physicochemical properties, including the primary particle size 174 
(Oberdörster et al. 2005), the surface treatment, e.g. presence and type of coatings (e.g. Warheit 175 
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et al. 2005), and the crystal form (e.g. Jiang et al. 2008). To comprehensively analyse their 176 
influences and dependencies, a sufficiently detailed documentation of these properties is required 177 
for the majority of the retained studies. Unfortunately, because of the paucity of data across the 178 
retained studies, the surface-related characteristics, e.g. coatings of pigmentary particles, could 179 
not be integrated. Therefore, only the primary particle size and the crystal form were analysed in 180 
relation to the toxic responses, an assumption that affects the numeric estimates. Further works 181 
should address those gaps. 182 
For primary particle size, the values reported by the authors of the studies were considered as 183 
such, although some discrepancies might occur in their characterisation across studies. It is 184 
noteworthy that in most studies, data about size distribution was missing or largely insufficient to 185 
allow for a comprehensive accounting of this aspect. When available, such information could 186 
however be useful to investigate the influence of the particle aggregation state on the potential 187 
toxicity of nanoparticles, and should thus be encompassed in future studies comparable to the 188 
current one. 189 
2.4. Expression of animal doses 190 
For all included experiments, each tested dose and its associated responses were individually 191 
treated. A similar method as the one developed by Gold et al. (1984) (CPDB website at 192 
http://potency.berkeley.edu/methods.html) was applied. All reported doses were translated into 193 
average daily chronic dose rates expressed in a mass unit of the particle intake per day (d) and kg 194 
body weight (kg-bw) for ingestion and inhalation exposure –see Equations 1 and 2, respectively: 195 
ia
ia
chronica CFBW
CFID
ID
×
×
= exp,,  (Equation 1) 196 
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ia
aia
chronica CFBW
CFIRC
ID
×
××
= exp,,  (Equation 2) 197 
where chronicaID ,  is the average daily chronic intake dose (e.g. mg/kg-bw/day) for a given animal 198 
a ; iaID ,  is the daily ingested dose (e.g. mg/day) used in the test with animal a  and exposure 199 
duration i ; expCF  is the correction factor for exposure time to translate the discontinuous regimen 200 
in animal test into an assumed continuous daily exposure used as target exposure (e.g. expCF  = 201 
D/7 x H/24, with D = days of weekly exposure and H = hours of daily exposure); aBW  is the 202 
body weight (kg-bw) of animal a  (reported in studies or default values taken from US-EPA 203 
(1988); iCF  is the dimensionless correction factor for duration of the exposure i  (subacute, 204 
subchronic, chronic; see below); iaC ,  is the concentrations (mg/m
3) used in the test with animal 205 
a  and exposure duration i ; aIR  is the inhalation rate of test animal a  in m
3/d (reported in US-206 
EPA 1988). 207 
The correcting factors iCF  from Vermeire et al. (1999, 2001) were used to adjust the 208 
duration of the exposure, with values for subacute-to-chronic factor of 5 and subchronic-to-209 
chronic ratio of 2. They are derived for oral NOAEL data but Vermeire et al. (2001) report their 210 
assumed applicability to systemic effects caused by inhalation or dermal exposures. These 211 
extrapolation factors were derived from investigating chemicals effects. In the absence of any 212 
data with regard to particles, it is assumed valid for the purpose of this study. Further work is 213 
needed to verify and/or refine that assumption. 214 
It is noteworthy that the approach to express doses as intake doses for both exposure routes 215 
differs from that used in some other studies (e.g. Brown et al. 2005; Kuempel et al. 2006; 216 
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Pauluhn 2011; Oller and Oberdörster 2010). In these, the dose expression also encompasses 217 
some elements of absorption by the receiving body. For example, in particle inhalation studies, 218 
Jarabek et al. (2005), Kuempel et al. (2006) and Oller and Oberdörster (2010) include the 219 
deposited fractions of particles in the lungs, which also depend on the agglomeration/aggregation 220 
state and can be calculated via e.g. a multiple-path particle dosimetry model (e.g. Asgharian et al. 221 
1995, 2001; Asgharian and Price 2007). In the current study, we intend to bring results from all 222 
exposure pathways on an equal basis. In practice, this can be done before or after absorption 223 
processes (e.g. after absorption from GI tract for ingestion route or from the depositions in the 224 
lungs). However, the absorption mechanisms are dependent on several parameters, including 225 
characteristics specific to both the particle type and the receiving animal/human body. Based on 226 
the often incomplete data available in the retrieved studies and the general lack of knowledge in 227 
the mechanisms governing particle absorptions, the determination of absorption fractions was 228 
disregarded for all considered exposure routes. All doses for inhalation and ingestion were 229 
therefore expressed as intake doses. The possibility to harmonise all doses as uptake doses, 230 
reflecting the amount of nanoparticles absorbed in the body via the lungs or the gastrointestinal 231 
tract, should however be explored in further studies, as it is deemed more consistent. 232 
 233 
2.5. Review of observed toxic responses 234 
As the toxic endpoints vary considerably across the selected studies, the observed toxic 235 
responses were reviewed for each single dose tested with focus on ensuring comparability and 236 
harmonisation across the studies. General selection criteria were thus defined, including: (i) 237 
evaluation of the incidence of adverse effects and not their severities, hence disregarding post-238 
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exposure monitoring/recovery periods, which could yield different toxicity characterisation in 239 
the data set but could difficultly be harmonised across studies (e.g. studies not addressing 240 
recovery vs. studies addressing it); (ii) evaluation of the toxic responses based on the stained 241 
sections and micrographs of exposed organs and tissues (e.g. incidence of necrosis) and/or the 242 
reported levels of serum biochemical values and haematological parameters (based on statistical 243 
significance when compared to controls), and the interpretation of histopathological findings 244 
reported by the authors of the studies; (iii) emphasis to identify actual adverse effects. With 245 
respect to the latter, the accumulation of macrophages was thus not deemed an adverse effect 246 
because it was regarded as a defence mechanism, which could be triggered by other causes than 247 
the exposure to the (nano)particles. Many experiment results were analysed based on the 248 
reported incidence of necrosis or apoptosis, both indicative of induced inflammation. Chronic 249 
alveolar inflammation was considered an adverse effect for lung toxicity. Statistically different 250 
(from controls) levels of neutrophils (PMN) or some enzymes, e.g. aspartate transaminase (AST) 251 
or alanine transaminase (ALT), indicative of liver toxicity and injury, were also considered as 252 
markers of adverse effects. All toxic endpoints were considered equally in this review and were 253 
not differentiated in the further analysis to allow retaining a sufficiently large pool of data. 254 
However, ways to account for their large diversities, and thus render the different doses (e.g. 255 
NOAELs), should be explored in future studies (ECHA, 2017). 256 
Each dose-specific experiment was thus flagged as either a NOAEL or a lowest-observed 257 
adverse effect level (LOAEL), or was not flagged if the experiment dose was lower (higher) than 258 
an already-flagged NOAEL (LOAEL) for the same experiment. Although tests within each 259 
single experiment were flagged as NOAEL or LOAEL (or not flagged), the data are in fact 260 
interval-censored and all flagged tests should be distinguished according to three groups, i.e. (1) 261 
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those with only an identified NOAEL (i.e. left-censored), (2) those with only an identified 262 
LOAEL (i.e. right-censored) and (3) those with both identified NOAEL and LOAEL in the same 263 
experiment (i.e. termed “interval-censored NOAEL/LOAEL” in the following). Therefore, the 264 
level at which an adverse effect occurs lies between NOAELs and LOAELs of tests belonging to 265 
group 3 (hence “interval censoring”), or lies above NOAELs of group 1 (how far above is 266 
unknown, hence “right-censoring”) or below LOAELs of group 2 (how far below is unknown, 267 
hence “left-censoring”). In the reporting and analysis of the results, the distinction between the 268 
NOAELs of groups 1 and 3 as well as that between the LOAELs of groups 2 and 3 were made by 269 
considering either the whole set of NOAEL/LOAEL data or the data set limited to interval-270 
censored NOAEL/LOAELs. 271 
 272 
2.6. Regression analyses 273 
Several parametric regression analyses were performed to investigate the relationships 274 
between the incidence of adverse effects and the primary size and the crystallinity of the TiO2 275 
particles: (i) a preliminary analysis of variance (ANOVA), (ii) multiple linear regression 276 
analyses, and (iii) a regression analysis accounting for the censored nature of the data (i.e. 277 
differentiating left-censored, right-censored and interval-censored data). Statistical software from 278 
the R system, version 3.2.3 (R Core Team, Vienna, AT), and statistical software Stata, v. 13 279 
(StataCorp LP, College Station, TX, USA), were used to perform these analyses.  280 
Based on the review of the toxic responses (see Section 2.5), ANOVA tests were carried out 281 
using the whole set of NOAEL/LOAEL data, testing the influence of the primary size of the 282 
particles, the exposure route, and the type of toxicity response to explain TiO2 toxicity. For these 283 
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ANOVA tests, the particles in our data set were grouped into two size groups (nano-range, i.e. 284 
below 100 nm, and micro- range, above 100 nm). 285 
Multiple linear regression (MLR) analyses were computed on the NOAEL and LOAEL 286 
identified through the review (see Section 2.5), and encompassed the following numerical and 287 
categorical variables: (i) the primary size of the particles, (ii) the crystal form (relevant to TiO2), 288 
(iii) the exposure route, (iv) the tested animal, and (v) the type of toxicity response (NOAEL or 289 
LOAEL). The analyses were separately conducted on the entire set of data as well as on the data 290 
set limited to interval-censored NOAEL/LOAEL values (see Section 2.5). In these regressions, 291 
the primary size of the particles was included as continuous variable. The generic model of the 292 
regression analysis describes NOAEL and can be expressed for an observation i with Equation 3: 293 
iancrystancrystroutespeciesroutespeciesisizei
XIdNOAEL eβββa +++= −−−−+ )(log)(log 1010  (Equation 3) 294 
with d the primary particle size, β size  the parameter expressing the slope for the dependence on 295 
primary particle size, β routespecies,  the parameter for given species and exposure route, conditioned 296 
with the Boolean variable routespeciesI , (0, 1), and β ancryst−  the parameter for anatase crystal form, 297 
conditioned with the content of anatase ancrystX −  (%) and ie  expressing a normal distribution with 298 
mean 0. When only exposure route was considered as a variable (i.e. no species differentiation; 299 
see Section 3.2), the parameter β routespecies, in Equation 1 is substituted by β route .  300 
To integrate the censored nature of the data into the regression analysis, an additional 301 
parametric regression analysis of the censored data was conducted (Klein 2003). Such type of 302 
models is commonly used for accelerated failure time modelling, and its explorative use here 303 
aims to test the relationships between the size variable and the absence or incidence of adverse 304 
14 
Laurent A., Harkema J., Andersen E. W., Owsianiak M., Vea E. B., Jolliet O., 2017. Human health no-effect levels 
of TiO2 nanoparticles as a function of their primary size. Journal of Nanoparticle Research 19, 130. 
DOI:10.1007/s11051-017-3816-8. 
effects defined as interval-censored, left-censored or right-censored data. The model expression 305 
for that censoring-based regression (CR) is the same as described in Equation 1. In addition to 306 
testing the statistical significance of the variables, the tested model can also describe the point 307 
where adverse effects start occurring, i.e. virtually the upper achievable NOAEL. 308 
The results of all regression tests were examined and interpreted based on the statistical 309 
significance of the parameters and the model as a whole (p-values < 0.05). In addition, multiple 310 
linear regression models were also validated using leave-one-out cross-validation procedure and 311 
characterised with the predictive squared correlation coefficient Q2. 312 
 313 
2.7. Extrapolations to human-equivalent doses 314 
Equivalent human intake doses, i.e. NOAELs for humans, were extrapolated from average 315 
daily chronic intake doses for the selected animal for ingestion and inhalation exposure routes –316 
see Equation 4.  317 
hum
a
ex
aex
hum BWAF
NOAEL
NOAEL ×=  (Equation 4) 318 
With exhumNOAEL  being the NOAEL expressed as average daily intake dose for humans (in 319 
mg/day/person) for chronic exposure route ex; exaNOAEL  the NOAEL expressed as average daily 320 
intake dose for animal a and chronic exposure route ex; aAF  the interspecies allometric factor 321 
for animal a ; and humBW Body weight (kg) of humans (70 kg; US-EPA 1988). 322 
 323 
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Interspecies extrapolation from animals to humans was performed by applying allometric 324 
factors (Gold et al. 1984, Jarabek et al. 2005, Rosenbaum et al. 2011, Vermeire et al. 1999, 2001, 325 
Vermeire et al. 1999). As defined by Vermeire et al. (2001), the interspecies factors include (i) a 326 
default distribution to account for variability in specific toxicokinetics and toxicodynamics, and 327 
(ii) a default factor to account for systemic differences between species caused by differences in 328 
body size and related basal metabolic rate. Vermeire et al. (2001) report a geometric mean of the 329 
latter equal to 1, thus reflecting the biological assumption that all species are equally sensitive. 330 
The interspecies allometric factors aAF  thus express the systemic differences between species 331 
after exposure. Three methods are commonly used to determine these factors, whether the 332 
extrapolations are based on body weight, surface area or caloric demand (Vermeire et al. 1999). 333 
In the current study, the recommendations of Vermeire et al. (1999, 2001), who indicate the 334 
preference of extrapolations based on calorific demands, were followed, with default values of 335 
aAF  equal to 4.1 (rats), 7.3 (mice) and 4.7 (hamster; own calculation). It is noteworthy that this 336 
is in contrast to some previous studies on nano-sized and micro-sized particles (e.g. Jarabek et al. 337 
2005; Kuempel et al. 2006), where the allometric factor is defined by the ratios of body weights 338 
between humans and animals for systemic effects, or by the ratios of lung masses or lung surface 339 
areas between humans and animals for effects in the respiratory tract.  340 
 341 
3. Results and discussion 342 
3.1. Review results 343 
The application of selection criteria to identify relevant in vivo studies for the review (see 344 
Methodology) led to shortlisting a total of 181 collected studies in 209 scientific publications to a 345 
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number of 21 retained in vivo studies addressing subacute, subchronic and chronic exposure to 346 
TiO2 particles via ingestion and inhalation routes (32 scientific publications; see Tables S1 and 347 
S2 and Supplementary Methods). The retained data correspond to 60 different tests, in which 17 348 
NOAELs and 26 LOAELs were identified (see Table 1). The range of particle sizes over the 349 
entire data set is 4 nm – 450 nm. The review details of these tests are documented in Tables S1 350 
and S2 for ingestion and inhalation exposure routes, respectively. 351 
 352 
Table 1 Summary of reviewed in vivo studies with ranges of NOAEL and LOAEL for TiO2 353 
particles. a 354 
Exposure 
routes 
Number of 
studies 
(papers) b 
Number 
of tests b 
Number of 
left-censored 
NOAEL data 
Number of 
right-censored 
LOAEL data 
Number of 
interval-censored 
NOAEL / LOAEL 
data 
NOAEL 
(LOAEL) ranges 
(mg/kg-bw/d) 
Ingestion 6 (6) 15 3 5 1 / 1 40 – 24000 (8 - 1000) 
Inhalation 15 (26) 45 7 14 6 / 6 0.0836 - 4.05 (0.0171 - 10.5) 
Total 
retrieved 21 (32) 60 10 19 7 / 7 - 
a For differentiation across species, see details in Tables S1 and S2. 355 
b Studies refer to a set of experiments performed by the same research group. The results of a study are 356 
sometimes disseminated in several papers, hence the higher number of papers than that of studies. Tests 357 
refer to experiments conducted on a given species exposed to a specific type of particles with a specific 358 
exposure level. 359 
 360 
3.2. Relationships between toxic effects and primary particle size of TiO2  361 
Unlike anticipated (see, e.g. Jiang et al., 2008), none of the statistical analyses of the 362 
correlation between the toxicity of TiO2 particles and their physicochemical properties showed 363 
that the crystallinity of TiO2 particles expressed a statistically-significant influence on their 364 
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toxicity when the primary particle size was also considered. A strong correlation was observed 365 
between the crystallinity and the primary size of the particles in the retained experiments (see 366 
Table S3), since small-sized particles were associated with higher proportions of anatase whereas 367 
larger-sized particles were dominantly in a rutile form. The crystallinity was therefore 368 
disregarded from further analysis in this study although its relationship with toxicity of the 369 
particles should still be explored in future research (Jiang et al. 2008). In the following 370 
subsections, the analysis was therefore centered on studying the relationships between the 371 
primary size and the toxicity of the particles. 372 
The overall trend illustrated in Figure 1A suggests an influence of particle size when 373 
classifying the data set into 2 size groups (nano-range, i.e. below 100 nm, and micro- range, 374 
above 100 nm). The two-way ANOVA analysis indeed revealed statistically significant 375 
differences between the size groups, classified into absence/occurrence of adverse effects, i.e. 376 
NOAEL or LOAEL (see Figure 1A; all data considered, regardless of their interval-censored 377 
nature) when all routes were combined (F2,40=2.96; p values of 0.039 and 0.27 for the effects of 378 
size and absence/occurrence of adverse effects, respectively). When only inhalation data are 379 
considered, both the size and the absence/occurrence of adverse effects become statistically 380 
significant (F2,30=14.4; p<0.005 in both cases; see Figure 1B). This suggests that in addition to 381 
the influence of the size, there might be some influence of the exposure route on nanoparticle 382 
toxicity. This influence was not found to be statistically significant in this ANOVA analysis 383 
probably due to low number of data points.  384 
 385 
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 386 
Fig. 1 Influence of the primary size on the occurrence of adverse toxic effect of TiO2 particles in 387 
nano- and micro-sized ranges for (a) the entire data set, and (b) the data set restricted to the 388 
inhalation exposure route. EFs indicated on the y-axis are either NOAEL or LOAEL data points 389 
(adjusted to average daily chronic intake doses in mg/kg-bw/d; see Table 1). Boxes indicate 25th 390 
and 75th percentiles, square and horizontal lines within the boxes indicate mean and median, 391 
respectively. Whiskers indicate inner out outer fence values assuming a default coefficient of 1.5, 392 
so that data points outside the fence values (in our study one data point) are considered outliers. 393 
Crosses indicate 2.5th and 95th percentiles. 394 
 395 
Multiple linear regressions were performed to further refine the ANOVA test (see Section 396 
2.6). Table 2 provides the results for four analyses made on either the entire data set (n= 43) or 397 
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the data set limited to interval-censored NOAEL/LOAEL (n=14), with and without species 398 
differentiation. The considered variables are able to explain between 88% and 92% (adjusted R2) 399 
of the data variability when restricting the dataset to the most reliable data with that interval-400 
censored NOAEL/LOAEL. When considering the entire dataset, data variability increases and 401 
the fraction explained is reduced to approximately 65%.  402 
Effect of particle size: Statistically significant associations are observed between NOAEL 403 
and size-variable for the restricted interval-censored data set, with significant (i.e. below 0.05) p-404 
values of 0.004 (test with exposure route differentiation) and 0.001 (test with both species and 405 
exposure route differentiation). When considering the entire dataset, the association with the 406 
size-variable is significant (p=0.009) when only exposure route is differentiated and marginally 407 
significant (p=0.049) when both route and species are differentiated. These results suggest a firm 408 
correlation between the primary size of the particle and its toxicity. Likewise, a marked 409 
differentiation between the absence or occurrence of adverse effects (i.e. NOAEL or LOAEL) is 410 
overall observed (see Table 2). 411 
 412 
Table 2 Results of MLR analysis for inhalation and ingestion exposure to TiO2 particles. a 413 
Parameter 
Only interval-
censored 
NOAEL/LOAEL 
(n=14) 
Exposure route 
differentiation 
Only interval-
censored 
NOAEL/LOAEL 
(n=14) 
Species and exposure 
route differentiation 
All NOAEL/LOAEL 
data (n=43) 
Exposure route 
differentiation 
All NOAEL/LOAEL 
data (n=43) 
Species and exposure 
route differentiation 
Intercept -1.80 (-2.69; -0.90) ** -2.31 (-3.32; 1.29) ** -1.20 (-2.00; -0.40) ** -1.234 (-2.02; -0.43) **  
Log Size 0.74 (0.30; 1.17) ** 0.87 (0.47 1.28) ** 0.57 (0.15; 0.99) ** 0.46 (0.002; 0.91) ** 
Inhalation  0 (reference, see intercept) NA 
0 (reference, see 
intercept) NA 
Ingestion 1.76 (1.23; 2.30) ** NA 1.90 (1.42; 2,39) ** NA 
Ingestion, 
mouse NA 1.97 (1.37; 2.57) ** NA 2.08 (1.36; 2.80) ** 
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Ingestion, rat NA NA NA 2.53 (1.64; 3.43) ** 
Inhalation, 
mouse NA 0.51 (0.04; 1.05) * NA 
0 (reference, see 
intercept) 
Inhalation, 
rat NA 0.141 (0.36; 0.64) NA 0.47 (-0.13; 1.08)  
Inhalation, 
hamster NA 
0 (reference, see 
intercept) NA 0.21 (-0.64; 1.05)  
LOAEL 0.73 (0.36; 1.09) ** 0.72 (0.40; 1.04) ** 0.31 (-0.12; 0.73)  0.21 (-0.25; 0.67)  
Adj. R2 0.884 0.918 0.648 0.656 
Q2 (LOO) 0.841 0.894 0.589 0.524 
p-value for 
model 1.47E-05 ** 5.55E-05 ** 1.41E-09 ** 2.79E-08 ** 
a Statistically-significant results, assumed with  p < 0.05, are indicated by asterisks “**”, results with  414 
0.05 < p < 0.1 are indicated by “*”. 95% confidence intervals (95% CI) are provided in brackets. NA: not 415 
applicable. 416 
 417 
The best estimate of the size parameter slope βsize that expresses the increase in the 418 
log10(NOAEL) as a function of the log10(particle size) varies between 0.46 and 0.87 (see Table 419 
2). This supports the observations that toxic effects continuously decrease as the primary particle 420 
size increases. These results imply that an exposure to TiO2 nanoparticles of 10-nm primary size 421 
would lead to toxic effects approximately 2.9-7.5 times higher than a same exposure to TiO2 422 
particles of 100-nm primary size (range of 1-19 when considering the positive 95% CIs reported 423 
in Table 2). This finding, especially the numerical estimates, should be considered with care 424 
because physicochemical properties other than the particle size and that are not investigated in 425 
the present study might significantly alter the reported trends. For example, the surface coatings 426 
is known to significantly influence the toxicity of the nanoparticles, and even though our review 427 
disregarded coated nanomaterials, the tested particles may still happen to be doped and/or 428 
affected by the test media, as these aspects are not always monitored and reported transparently 429 
in toxicological studies (Clark et al., 2012; Warheit et al., 2005; Yang et al. 2014). 430 
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This trend of a positive slope βsize can also be observed when performing regression analyses 431 
taking into account the censored nature of the data (i.e. Censoring-based Regression – CR 432 
analysis; see Section 2.6), where positive values of the slope βsize are obtained (0.80 and 0.41 for 433 
species-route differentiation and only route differentiation, respectively; see Tables S4 and S5). 434 
However, it should be noted that these CR tests, although deemed the most consistent when 435 
taking the entire set of available data, did not reveal any statistical significance with p-values 436 
above 0.05 (Tables S4 and S5). A strong dependence on the inclusion and exclusion of data in 437 
this statistical test (data not shown) suggests that further attempts at the CR application should be 438 
made when larger and more consistent data sets become available. 439 
Exposure route: Figure 2 plots the size-differentiated NOAEL functions obtained from the 440 
results of the different regression analyses. As reflected by the highly significant coefficient for 441 
ingestion (versus inhalation) of close to 1.8-1.9 in both experiment only differentiating the 442 
exposure route, the NOAEL values are approximately 60-80 times lower for inhalation exposure 443 
than for ingestion. As also illustrated in Figure 2, the variations between the estimates of the 444 
slope βsize are strongly dependent on the data set considered and whether or not only interval-445 
censored NOAEL/LOAEL data are considered (thus disregarding left- and right-censored 446 
NOAEL and LOAEL data points). Accounting for the entire data set (i.e. 43 data points) 447 
substantially extends the number of data, whereas the data set limited to interval-censored data 448 
(i.e. 14 data points) is deemed more accurate. 449 
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 450 
Fig. 2 NOAEL resulting from regression analyses for inhalation and ingestion exposure to TiO2 451 
particles (size range: 4-450 nm). Inclusion of different data sets (all data or interval-censored 452 
NOAEL/LOAEL only) and regression tests (multiple linear regression, MLR, or censoring-based 453 
regression, CR) differentiate the results from the regression tests, i.e. parameter values in 454 
Equation 4, and hence the different curves. Interval-censored regression data accounting for the 455 
censored nature of the data are only presented for indicative purposes as no statistically-456 
significant slope for the size were observed (see Tables S4 and S5). 457 
 458 
Species differentiation: Differentiating the number of species in addition to the exposure 459 
route only slightly increases the adjusted R2 for the restricted set limited to interval-censored 460 
NOAELs/LOAELs, whereas it does not bring any increase in adjusted R2 when considering the 461 
entire data set. With consideration to the restricted data set, for which there are little data for a 462 
relatively large number of variables, a regression analysis made with only a differentiation 463 
between exposure routes seems more appropriate.  464 
Particle size (diameter in nm)
1 10 100 1000
A
ve
ra
ge
 d
ai
ly
 c
hr
on
ic
 in
ta
ke
 d
os
e
N
O
A
E
L 
(m
g/
kg
-b
w
/d
)
10-2
10-1
100
101
102
103
MLR, all data - Inhalation
MLR, all data - Ingestion 
MLR, interval-censored NOAEL/LOAEL - Inhalation
MLR, interval-censored NOAEL/LOAEL - Ingestion
CR, all data - Inhalation
CR, all data - Ingestion
23 
Laurent A., Harkema J., Andersen E. W., Owsianiak M., Vea E. B., Jolliet O., 2017. Human health no-effect levels 
of TiO2 nanoparticles as a function of their primary size. Journal of Nanoparticle Research 19, 130. 
DOI:10.1007/s11051-017-3816-8. 
Albeit their limitation to the case of TiO2 nanoparticles, our findings thus provide two major 465 
advances in the assessment of the toxic effects of nanoparticles: (i) a quantitative measure of the 466 
association between toxic effects and primary sizes of nanoparticles; and (ii) an expression of 467 
toxic effects in a meaningful metric. Many studies have reported the different magnitudes of 468 
effects on animals following exposure to different sizes of nanoparticles or to either nano-scale 469 
or micro-scale particles, but none managed to quantify this difference for entire size ranges, thus 470 
providing continuity and allowing for useful predictions. Furthermore, the utilization of mass-471 
based metrics alone have been demonstrated not to be valid for capturing the effects of 472 
nanoparticles, and other complementary metrics based on surface area or particle numbers have 473 
been proposed to account for the particle sizes (Oberdörster et al. 2005). The above findings 474 
advance towards the determination of a meaningful, operational metric to express exposure 475 
levels, even though it only relies on the study of the primary size and ignores potential influences 476 
of other physicochemical properties of nanoparticles. The mass-based exposure levels (translated 477 
into intake doses) are expressed as a function of the primary particle size, thus implicitly 478 
accounting for the differences in the surface areas and particle numbers. Even for the inhalation 479 
pathway, in which the absorption is strongly dependent on the state of agglomeration and 480 
aggregation, aggregates of same sizes but with different primary sizes can lead to different toxic 481 
responses (Ferin et al. 1992), thus indicating possible disaggregation mechanisms after intake 482 
and attesting the strong influence of the primary particle size in the toxic effects. This therefore 483 
supports our assertion that, given the current state of knowledge, the expression of NOAEL as a 484 
function of the primary size as illustrated in Figure 2 can adequately capture the nano-scale-485 
specific toxicity of TiO2 particles while also allowing characterization of micro-sized particles, 486 
and thus address the metrics issue raised in earlier studies. Further research is however needed to 487 
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explore how the inclusion of more physicochemical properties can refine this expression of the 488 
NOAEL and to what extent this finding applies to other nanoparticles. 489 
 490 
3.3. Implications for assessing human health risks and impacts 491 
3.3.1. Derivation of human NOAEL 492 
A direct consequence of the aforementioned findings is the opportunity to determine 493 
NOAEL values for humans as function of the primary particle sizes. Based on the regression 494 
analyses in Section 3.2.2, the statistical results from the data set limited to the interval-censored 495 
NOAEL/LOAEL data that only distinguish between exposure routes without species 496 
differentiation were retained as basis for deriving the human NOAEL. These results presented 497 
high statistical significance for the different variable estimates. As reflected in Figure S1, they 498 
also show conservative estimates once the animal data were converted into human-equivalent-499 
exposure levels, compared to the use of the entire data set. Within the data-defined size range (4-500 
450 nm), Equations 5 and 6 express these relationships for TiO2 for both inhalation and ingestion 501 
routes, respectively (with d the primary size of the particles in nm; and NOAELhum in 502 
mg/person/day). 503 
( ) 796.0110680.1)(log796.0620.21070 dNOAEL dinhhum ××=


= −×+−  (Equation 5) 504 
( ) 796.0567.6)(log796.0028.11070 dNOAEL dinghum ×=


= ×+−   (Equation 6) 505 
 506 
It should be noted that the conversion to human exposure levels was performed on the 507 
original data. Therefore the run of new regression analyses was required to obtain the parameter 508 
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estimates although the results are very similar to those reported in Table 2 (i.e. statistical 509 
significance observed for all parameters and slope changed from 0.74 to 0.80; see Table S6). 510 
Because of the large uncertainties inherent to the determination of Equation 5 and 6 (see Section 511 
2 and regression result analysis in Section 3.2.2), the above equations are not intended to model 512 
and predict human NOAELs as a default method. However, they are believed to present a useful 513 
and complementary approach to existing approaches encompassing reviews and selections of 514 
specific toxicological test results (e.g. Christensen et al. 2011), and are deemed relevant for 515 
screening purposes in the evaluation of risks and impacts of TiO2 nanoparticles (see following 516 
Section 3.3.2). 517 
 518 
3.3.2. Possible use in RA 519 
A major concern about health effects of nanoparticles stems from potential occupational and 520 
consumer exposure (via inhalation and ingestion). As illustrated in Figure 3, the findings of this 521 
study show a relatively good agreement with the exposure limits recommended by the National 522 
Institute of Occupational Safety and Health (NIOSH) once these are translated into intake doses 523 
(Supplementary Methods and NIOSH 2011). For inhalation of TiO2 (blue curves), the 524 
discontinuous exposure NIOSH thresholds and ranges, which differentiate the nano-scale and the 525 
micro-scale domains based on particle archetypes (NIOSH 2011), closely follow the proposed 526 
continuous size-dependent NOAELs. When considering the data ranges of the present study (i.e. 527 
4-450 nm), the current study tends to yield more conservative estimates in the lower nano-sized 528 
and micro-sized ranges for inhalation. Overall, these comparisons therefore suggest that the 529 
findings are consistent with existing recommendations (e.g. NIOSH 2011) and epidemiological 530 
observations (e.g. Boffetta et al. 2004), although adjustments in recommended exposure 531 
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thresholds should be envisaged to integrate a continuous size dependency and more conservative 532 
estimations. 533 
With regard to ingestion exposure, some concerns have emerged with the ingestion of TiO2 as 534 
food additive (i.e. E171; primarily micro-sized). Although it could not establish an acceptable 535 
daily intake, the European Food Safety Authority (EFSA) Scientific Panel on Food Additives 536 
and Nutrient Sources recently highlighted a NOAEL of 2250 mg TiO2/kg-bw/d obtained for rats 537 
exposed in a chronic study (103 weeks) to ingestion of E171 (EFSA, 2016; NCI, 1979). When 538 
translated into human-equivalent intake doses (see Section 2.7), this resulted in a human NOAEL 539 
1-2 orders of magnitude higher than our results for the same size range –see Figure 3. While 540 
indicating the conservative nature of this NOAEL, this difference may be explained by the 541 
different properties of the food additive E171 and the TiO2 nanoparticles tested in the other 542 
ingestion exposure studies supporting our results (e.g. rutile form, etc.; see Table S1; see also 543 
Yang et al., 2014). It is also noteworthy that in actual exposure situations, an important 544 
proportion of the particles would remain sorbed to the food matrix during the digestion process 545 
and may thus not be available for absorption through the gastrointestinal tract. In contrast, 546 
nanoparticles used in toxicological studies are typically not bound to any matrix, which may 547 
result in a higher absorption rate. Further investigation is therefore required to evaluate the actual 548 
toxic effects of nanoparticles present in consumer products (Nowack et al. 2012; EFSA, 2016; 549 
Yang et al., 2014). 550 
 551 
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 552 
Fig. 3 Comparisons of NOAEL for humans for chronic inhalation and ingestion exposure to 553 
nano-sized and micro-sized TiO2 particles (NOAEL expressed as average daily intake doses in 554 
mg/person/day), and assuming that coatings on pigmentary particles do not lead to artefacts (see 555 
Section 2.3). The slope value for TiO2 particles is 0.796 (95% CI: 0.43-1.16). External data were 556 
used to compare with the results from the current study (ingestion: NOAEL value for E171 557 
highlighted by EFSA ANS Panel (2016); inhalation: epidemiological study by Bofetta et al. 558 
(2004); inhalation: recommended thresholds by NIOSH (2011)). The hatched area illustrates the 559 
range of inhalation exposure levels corresponding to NOAELs for noncarcinogenic effects as 560 
identified by NIOSH (2011); the blue-dotted line indicates the recommended NIOSH thresholds 561 
relating to cancer effects and regarded as default (NIOSH 2011). Background details pertaining 562 
to these graphs are documented in Table S6 and in Supplementary Methods.  563 
 564 
The dependence of the NOAEL on the primary size of the particles, including 95% 565 
confidence intervals, allows making refined, case-specific human health risk assessments, 566 
bringing more consistency to earlier attempts (Christensen et al. 2011; Kuempel et al. 2012; Som 567 
et al. 2013). Exposure situations, which are typically defined for a specific type of nanoparticles, 568 
can thus be compared to the human NOAEL obtained across a range of primary sizes. Table 3 569 
illustrates the application of the approach to occupational exposures to TiO2 nanoparticles. 570 
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Derived margins of exposure are observed to be well below potential uncertainty factors of 100 571 
or 1000 for occupational studies. It suggests that present TiO2 exposure may be high for workers, 572 
although occupational risks may be mitigated by the use of respiratory protection (see Table 3).  573 
 574 
Table 3 Illustrative application of the developed NOAEL approach for human health risk 575 
assessment of TiO2 occupational exposure situations. a 576 
Exposure situations 
Average daily intake 
(mg/person/day) 
NOAELup – intake b 
(mg/person/day) Margin of Exposure 
Collection of TiO2 (manufacturing) 
– without respiratory protection  
6.3E-2 1.2 
(0.5 – 3.0) 
19.3 
(7.8 – 47.5) 
Collection of TiO2 (manufacturing) 
– with respiratory protection  
3.4E-6 
1.2 
(0.5 – 3.0) 
3.6E+5 
(1.4E+5 – 8.8E+5) 
Bagging of TiO2 (manufacturing) 3.2E-1 
2.5 
(0.7 – 8.7) 
7.9 
(2.3 – 27.0) 
a Background details pertaining to these results are documented in Supplementary Methods; 95% 577 
confidence intervals are given in brackets for NOAEL and resulting margins of exposure. Data for 578 
occupational exposure data extracted from Koivisto et al. (2012a, b). Primary sizes of 12 and 30 nm were 579 
considered for collection and bagging of TiO2, respectively (see details in Supplementary Methods and 580 
Equations 5 and 6).  581 
 582 
3.3.3. Possible use in LCIA 583 
In line with common practice in life cycle impact assessment (e.g. Rosenbaum et al. 2011), 584 
Equations 5 and 6 can also be used to calculate effective doses ED50, i.e. chronic doses causing 585 
an adverse effect probability of 50%, to allow the calculation of characterization factors for TiO2 586 
particles, see for example Ettrup et al. (2016). 587 
 588 
4. Conclusions and outlook 589 
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By demonstrating that it is feasible to integrate physicochemical properties into the 590 
definition of NOAEL, our proposed approach and its application to TiO2 nanoparticles, albeit 591 
limited due to the difficulties surrounding coatings, can provide support for risk assessment of 592 
nanomaterials and life cycle assessment of nanoproducts. Until more comprehensive 593 
occupational human exposure and response data become available, our work can aid check 594 
and/or develop risk and life cycle assessment guidelines to ensure low risk exposures for 595 
consumers and workers. We therefore regard this study as a first step towards making use of the 596 
already large and increasing body of toxicological studies on nanoparticles and thus enable more 597 
consistent risk assessments and life cycle assessments. 598 
However, our study clearly reflected that more data are required to (i) refine the assumptions 599 
performed for translating and harmonizing the tested doses across different experimental settings 600 
(e.g. harmonizing the diversity of toxic endpoints) and for deriving chronic NOAELs for humans 601 
(see Sections 2.1-2.7 and Supplementary Methods); (ii) match the tested particles with those that 602 
are present in consumer products or subject to worker exposure; and (iii) integrate in the 603 
proposed methodology more toxicological data and encompass more physicochemical properties. 604 
Increasing consistency in reporting practice for toxicological studies, as recommended by Clark 605 
et al. (2012), should allow for studying a larger set of relevant particle properties, e.g. surface 606 
properties like coatings. The present approach should also be applied to other relevant types of 607 
nanoparticles, like silica, silver or carbon-based nanoparticles, ultimately contributing to holistic 608 
appraisals of the risks and impacts of nanotechnologies. 609 
 610 
5. Electronic Supplementary Materials 611 
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Electronic Supplementary Materials, including Supplementary Tables, Supplementary 612 
Figure and Supplementary Methods, accompanies this paper. The Supplementary Tables report 613 
the detailed results from the application of the methodology to micro- and nano-sized TiO2 614 
particles. The Supplementary Methods contain an account of the methodology for analyzing the 615 
relationships between nanoparticle toxicity and their physicochemical properties, as 616 
complementary to the Methods section. The Supplementary Methods also document the 617 
background data for the examples illustrating potential applications of the results to risk 618 
assessment studies. 619 
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